CNS Drugs

, Volume 29, Issue 5, pp 383–395 | Cite as

Topiramate in Alcohol Use Disorders: Review and Update

  • Riccardo GuglielmoEmail author
  • Giovanni Martinotti
  • Marianna Quatrale
  • Lucia Ioime
  • Irket Kadilli
  • Marco Di Nicola
  • Luigi Janiri
Review Article


To date, a limited number of pharmacological agents exist to treat alcohol use disorders (AUDs), and there is growing interest in new therapeutic tools. In this framework, topiramate may represent a useful treatment option, although its use is not yet approved for AUDs. The main focus of this review is to discuss all the existing data supporting the use of topiramate in AUDs, with an emphasis on the most recent and relevant clinical implications. In addition, the profile of the alcoholic patient who may benefit more from the use of topiramate is outlined. In this regard, the authors conducted a PubMed search of clinical human studies published in English using the following key words: topiramate alcohol dependence, topiramate alcohol withdrawal and topiramate alcoholism. The evidence suggests that topiramate could be an effective treatment option for the management of AUDs, while there are limited results for its use to treat alcohol withdrawal syndrome. In particular, topiramate shows a greater beneficial effect in subjects with a typology of craving characterised by drinking obsessions and automaticity of drinking. Topiramate, within the dosage range of 75–300 mg/day, could be considered as a first-line treatment option for the management of AUDs. Its use appears to be safe and well-tolerated, especially in light of very recent findings.


Topiramate Naltrexone Memantine Disulfiram Acamprosate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors thank Rita Santacroce for language revision.

Conflict of interest

Drs. R. G., G. M., M. Q., L. I., I. K., M. D. N. and L. J., report no proprietary or commercial interest in any product mentioned or concept discussed in this article. In addition, we state that no funding was used to assist with the preparation of this manuscript.


  1. 1.
    Valenzuela CF. Alcohol and neurotransmitter interactions. Alcohol Health Res World. 1997;21(2):144–8.PubMedGoogle Scholar
  2. 2.
    Mueller TI, Stout RL, Rudden S, Brown RA, Gordon A, Solomon DA, et al. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res. 1997;21(1):86–92.PubMedCrossRefGoogle Scholar
  3. 3.
    Longo LP, Campbell T, Hubatch S. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. J Addict Dis. 2002;21(2):55–64.PubMedCrossRefGoogle Scholar
  4. 4.
    Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361(9370):1677–85.PubMedCrossRefGoogle Scholar
  5. 5.
    Martinotti G, Di Nicola M, Romanelli R, Andreoli S, Pozzi G, Moroni N, et al. High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients. Hum Psychopharmacol. 2007;22(3):149–56.PubMedCrossRefGoogle Scholar
  6. 6.
    Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68(11):1691–700.PubMedCrossRefGoogle Scholar
  7. 7.
    Guglielmo R, Martinotti G, Clerici M, Janiri L. Pregabalin for alcohol dependence: a critical review of the literature. Adv Ther. 2012;29(11):947–57.PubMedCrossRefGoogle Scholar
  8. 8.
    Johnson BA, Ait-Daoud N. Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. Curr Pharm Des. 2010;16(19):2103–12.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Kenna GA, Lomastro TL, Schiesl A, Leggio L, Swift RM. Review of topiramate: an antiepileptic for the treatment of alcohol dependence. Curr Drug Abuse Rev. 2009;2(2):135–42.PubMedCrossRefGoogle Scholar
  10. 10.
    Olmsted CL, Kockler DR. Topiramate for alcohol dependence. Ann Pharmacother. 2008;42(10):1475–80.PubMedCrossRefGoogle Scholar
  11. 11.
    De Sousa A. The role of topiramate and other anticonvulsants in the treatment of alcohol dependence: a clinical review. CNS Neurol Disord Drug Targets. 2010;9(1):45–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Johnson BA. Uses of topiramate in the treatment of alcohol dependence. Expert Rev Neurother. 2004;4(5):751–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41(Suppl 1):S3–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Kawasaki H, Tancredi V, D’Arcangelo G, Avoli M. Multiple actions of the novel anticonvulsant drug topiramate in the rat subiculum in vitro. Brain Res. 1998;807(1–2):125–34.PubMedCrossRefGoogle Scholar
  15. 15.
    White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia. 2000;41(Suppl 1):S17–20.PubMedCrossRefGoogle Scholar
  16. 16.
    Angehagen M, Ronnback L, Hansson E, Ben-Menachem E. Topiramate reduces AMPA-induced Ca(2+) transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures. J Neurochem. 2005;94(4):1124–30.PubMedCrossRefGoogle Scholar
  17. 17.
    Zhang X, Velumian AA, Jones OT, Carlen PL. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia. 2000;41(Suppl 1):S52–60.PubMedCrossRefGoogle Scholar
  18. 18.
    Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia. 2000;41(Suppl 1):S35–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Herrero AI, Del Olmo N, Gonzalez-Escalada JR, Solis JM. Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology. 2002;42(2):210–20.PubMedCrossRefGoogle Scholar
  20. 20.
    Wauquier A, Zhou S. Topiramate: a potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res. 1996;24(2):73–7.PubMedCrossRefGoogle Scholar
  21. 21.
    McElroy SL, Arnold LM, Shapira NA, Keck PE Jr, Rosenthal NR, Karim MR, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160(2):255–61.PubMedCrossRefGoogle Scholar
  22. 22.
    Rho JM, Sankar R. The pharmacologic basis of antiepileptic drug action. Epilepsia. 1999;40(11):1471–83.PubMedCrossRefGoogle Scholar
  23. 23.
    Schiffer WK, Gerasimov MR, Marsteller DA, Geiger J, Barnett C, Alexoff DL, et al. Topiramate selectively attenuates nicotine-induced increases in monoamine release. Synapse. 2001;42(3):196–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Garnett WR. Clinical pharmacology of topiramate: a review. Epilepsia. 2000;41(Suppl 1):S61–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Mula M. Anticonvulsants–antidepressants pharmacokinetic drug interactions: the role of the CYP450 system in psychopharmacology. Curr Drug Metab. 2008;9(8):730–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry. 2004;61(9):905–12.PubMedCrossRefGoogle Scholar
  27. 27.
    Ma JZ, Ait-Daoud N, Johnson BA. Topiramate reduces the harm of excessive drinking: implications for public health and primary care. Addiction. 2006;101(11):1561–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298(14):1641–51.PubMedCrossRefGoogle Scholar
  29. 29.
    Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, et al. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med. 2008;168(11):1188–99.PubMedCrossRefGoogle Scholar
  30. 30.
    Rubio G, Ponce G, Jimenez-Arriero MA, Palomo T, Manzanares J, Ferre F. Effects of topiramate in the treatment of alcohol dependence. Pharmacopsychiatry. 2004;37(1):37–40.PubMedCrossRefGoogle Scholar
  31. 31.
    Rubio G, Martinez-Gras I, Manzanares J. Modulation of impulsivity by topiramate: implications for the treatment of alcohol dependence. J Clin Psychopharmacol. 2009;29(6):584–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Huguelet P, Morand-Collomb S. Effect of topiramate augmentation on two patients suffering from schizophrenia or bipolar disorder with comorbid alcohol abuse. Pharmacol Res. 2005;52(5):392–4.PubMedCrossRefGoogle Scholar
  33. 33.
    Chiu YH, Lee TH, Shen WW. Use of low-dose topiramate in substance use disorder and bodyweight control. Psychiatry Clin Neurosci. 2007;61(6):630–3.PubMedCrossRefGoogle Scholar
  34. 34.
    Fernandez Miranda JJ, Marina Gonzalez PA, Montes Perez M, Diaz Gonzalez T, Gutierrez Cienfuegos E, Antuna Diaz MJ, et al. Topiramate as add-on therapy in non-respondent alcohol dependant patients: a 12 month follow-up study. Actas Esp Psiquiatr. 2007;35(4):236–42.PubMedGoogle Scholar
  35. 35.
    Likhitsathian S, Uttawichai K, Booncharoen H, Wittayanookulluk A, Angkurawaranon C, Srisurapanont M. Topiramate treatment for alcoholic outpatients recently receiving residential treatment programs: a 12-week, randomized, placebo-controlled trial. Drug Alcohol Depend. 2013;133(2):440–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Kampman KM, Pettinati HM, Lynch KG, Spratt K, Wierzbicki MR, O’Brien CP. A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend. 2013;133(1):94–9.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    De Sousa AA, De Sousa J, Kapoor H. An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence. J Subst Abuse Treat. 2008;34(4):460–3.PubMedCrossRefGoogle Scholar
  38. 38.
    Florez G, Garcia-Portilla P, Alvarez S, Saiz PA, Nogueiras L, Bobes J. Using topiramate or naltrexone for the treatment of alcohol-dependent patients. Alcohol Clin Exp Res. 2008;32(7):1251–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Baltieri DA, Daro FR, Ribeiro PL, de Andrade AG. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction. 2008;103(12):2035–44.PubMedCrossRefGoogle Scholar
  40. 40.
    Florez G, Saiz PA, Garcia-Portilla P, Alvarez S, Nogueiras L, Bobes J. Topiramate for the treatment of alcohol dependence: comparison with naltrexone. Eur Addict Res. 2011;17(1):29–36.PubMedCrossRefGoogle Scholar
  41. 41.
    Arbaizar B, Diersen-Sotos T, Gomez-Acebo I, Llorca J. Topiramate in the treatment of alcohol dependence: a meta-analysis. Actas Esp Psiquiatr. 2010;38(1):8–12.PubMedGoogle Scholar
  42. 42.
    Blodgett JC, Del Re AC, Maisel NC, Finney JW. A meta-analysis of topiramate’s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res. 2014;38(6):1481–8.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013;108(2):275–93.PubMedCentralPubMedCrossRefGoogle Scholar
  44. 44.
    Paparrigopoulos T, Tzavellas E, Karaiskos D, Kourlaba G, Liappas I. Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study. BMC Psychiatry. 2011;11:41.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Martinotti G, Di Nicola M, De Vita O, Hatzigiakoumis DS, Guglielmo R, Santucci B, et al. Low-dose topiramate in alcohol dependence: a single-blind, placebo-controlled study. J Clin Psychopharmacol. 2014;34(6):709–15.PubMedCrossRefGoogle Scholar
  46. 46.
    Miranda R Jr, MacKillop J, Monti PM, Rohsenow DJ, Tidey J, Gwaltney C, et al. Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res. 2008;32(3):489–97.PubMedCrossRefGoogle Scholar
  47. 47.
    Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ, et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry. 2014;171(4):445–52.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Ray LA, Miranda R Jr, MacKillop J, McGeary J, Tidey JW, Rohsenow DJ, et al. A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol. 2009;17(2):122–9.PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Rustembegovic A, Sofic E, Kroyer G. A pilot study of Topiramate (Topamax) in the treatment of tonic–clonic seizures of alcohol withdrawal syndromes. Med Arh. 2002;56(4):211–2.PubMedGoogle Scholar
  50. 50.
    Krupitsky EM, Rudenko AA, Burakov AM, Slavina TY, Grinenko AA, Pittman B, et al. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res. 2007;31(4):604–11.PubMedGoogle Scholar
  51. 51.
    Littleton J. Neurochemical mechanisms underlying alcohol withdrawal. Alcohol Health Res World. 1998;22(1):13–24.PubMedGoogle Scholar
  52. 52.
    Prado-Lima PA. Pharmacological treatment of impulsivity and aggressive behaviour [in Portuguese]. Rev Bras Psiquiatr. 2009;31(Suppl 2):S58–65.PubMedGoogle Scholar
  53. 53.
    Leung KS, Cottler LB. Treatment of pathological gambling. Curr Opin Psychiatry. 2009;22(1):69–74.PubMedCrossRefGoogle Scholar
  54. 54.
    McElroy SL, Guerdjikova AI, Martens B, Keck PE Jr, Pope HG, Hudson JI. Role of antiepileptic drugs in the management of eating disorders. CNS Drugs. 2009;23(2):139–56.PubMedCrossRefGoogle Scholar
  55. 55.
    Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive–compulsive disorder. J Clin Psychiatry. 2011;72(5):716–21.PubMedCrossRefGoogle Scholar
  56. 56.
    Cloninger CR, Svrakic DM, Przybeck TR. A psychobiological model of temperament and character. Arch Gen Psychiatry. 1993;50(12):975–90.PubMedCrossRefGoogle Scholar
  57. 57.
    Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, Allgulander C, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive–compulsive and post-traumatic stress disorders—first revision. World J Biol Psychiatry. 2008;9(4):248–312.PubMedCrossRefGoogle Scholar
  58. 58.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders, DSM-IV. 4th ed. Washington, DC: American Psychiatric Association; 1994.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Riccardo Guglielmo
    • 1
    • 4
    Email author
  • Giovanni Martinotti
    • 2
  • Marianna Quatrale
    • 1
  • Lucia Ioime
    • 1
    • 3
  • Irket Kadilli
    • 1
  • Marco Di Nicola
    • 1
  • Luigi Janiri
    • 1
  1. 1.Department of Geriatrics, Neuroscience and Orthopedics, Institute of PsychiatryCatholic University Medical School of RomeRomeItaly
  2. 2.Department of Neuroscience and ImagingUniversity “G. D’Annunzio”ChietiItaly
  3. 3.Department of Human ScienceLumsa University of RomeRomeItaly
  4. 4.Calvi RisortaItaly

Personalised recommendations